All posts tagged: AIdesigned

AI-designed drug reduces fentanyl consumption in animal models by targeting serotonin receptors

AI-designed drug reduces fentanyl consumption in animal models by targeting serotonin receptors

A recent study published in the Proceedings of the National Academy of Sciences suggests that a novel drug developed using artificial intelligence can significantly reduce fentanyl consumption in animal models. The experimental medication targets specific serotonin receptors in the brain to restore neural pathways altered by addiction. These findings provide evidence that this new compound could eventually offer a non-addictive treatment option for people experiencing opioid use disorder. Opioid use disorder currently affects millions of people, with synthetic opioids like fentanyl driving a severe public health crisis. Seeking alternative treatments, scientists focused on creating a therapy that addresses the neurological changes caused by addiction without relying on opioid-based medications. “New therapeutics for opioid use disorder are desperately needed,” said study author Christie D. Fowler, a chancellor’s fellow and professor in the Department of Neurobiology and Behavior at the University of California, Irvine. “Just about everyone has been impacted by the opioid epidemic. These are people’s mothers, fathers, sisters, brothers, sons, and daughters.” Fowler, who also serves as the co-director of the UC Irvine Center for …

AI-Designed Drugs by a DeepMind Spinoff Are Headed to Human Trials

AI-Designed Drugs by a DeepMind Spinoff Are Headed to Human Trials

Google DeepMind’s AlphaFold has already revolutionized scientists’ understanding of proteins. Now, the ability of the platform to design safe and effective drugs is about to be put to the test. Isomorphic Labs, the UK-based biotech spinoff of Google DeepMind, will soon begin human trials of drugs designed by its Nobel Prize–winning AI technology. “We’re gearing up to go into the clinic,” Isomorphic Labs president Max Jaderberg said on April 16 at WIRED Health in London. “It’s going to be a very exciting moment as we go into clinical trials and start seeing the efficacy of these molecules.” Jaderberg did not elaborate on the timeline, but it’s later than the company had planned to initiate human studies. Last year, CEO Demis Hassabis said it would have AI-designed drugs in clinical trials by the end of 2025. Isomorphic Labs was founded in 2021 as a spinoff from Alphabet’s AI research subsidiary, Google DeepMind. The company uses DeepMind’s AlphaFold, a groundbreaking AI platform that predicts protein structures, for drug discovery. Built from 20 different amino acids, proteins are …

A I-designed proteins may help spot cancer

A I-designed proteins may help spot cancer

Sangeeta Bhatia, SM ’93, PhD ’97, a senior author of a paper on the work with her former student Ava Amini ’16, a principal researcher at Microsoft Research, led the MIT team that came up with the idea of such particles over a decade ago. But earlier efforts used trial and error to identify peptides that would be cleaved by specific proteases, and the results could be ambiguous. With AI, peptides can be designed to meet specific criteria. “If we know that a particular protease is really key to a certain cancer, and we can optimize the sensor to be highly sensitive and specific to that protease, then that gives us a great diagnostic signal,” Amini says.  Bhatia’s lab is now working with ARPA-H on an at-home kit that could potentially detect 30 types of early cancer. Peptides designed using the model could also be incorporated into cancer therapeutics. Source link